BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jul 19, 2004
 |  BioCentury  |  Product Development

Chasing the path of Gleevec resistance

By any definition, Gleevec imatinib from Novartis AG has been a success as a treatment for chronic myeloid leukemia. However, while the drug has shown minimal toxicity, increased resistance is being encountered. Bristol-Myers Squibb Co. is developing a next-generation version that has been active in Gleevec-resistant models of CML.

Gleevec, which Novartis (NVS; SWX:NOVN, Basel, Switzerland) markets as Glivec in Europe, is a small molecule inhibitor of the Bcr-Abl tyrosine kinase, a mutated protein that is permanently activated in CML. The drug prevents overexpression of Abl by attaching to the ATP-binding site, thus inactivating the protein.

Clinical resistance to Gleevec is a result of point mutations in the ATP-binding domain of the Abl gene that interfere...

Read the full 579 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >